Vol. 28 No.1 – 2014 Best New Investigator Award: Development Update: A Promising Surgical Procedure

Jul 7, 2014

Michael Paukshto, PhD, CTO and co-founder of Fibralign Corporation, was awarded the 2014 Best New Investigator Award at the 11th Biennial NLN International Conference.

Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge Collagen Matrix in its GMP facility located in Union City, California.

Fibralign Announces CE Mark Approval for BioBridge®

Fibralign Announces CE Mark Approval for BioBridge®

European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...

read more
Fibralign Announces Strategic Partnership with Terumo

Fibralign Announces Strategic Partnership with Terumo

Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...

read more
Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign Awarded SBIR Phase IIS from Department of Defense

Fibralign announced today that it has been awarded a Small Business Innovation Research (SBIR) Sequential Phase II (Phase IIS) from the Department of Defense (DoD) Defense Health Program (DHP). This two-year grant provides $996,609 in funding to continue advancing...

read more